The genetics of familial hypercholesterolemia and emerging therapies

Area of Science:

• Genetics
• Cardiology
• Biochemistry

Background:

• Familial hypercholesterolemia (FH) is an inherited condition causing severely elevated LDL cholesterol from birth.
• Genetic mutations in LDL receptor, apolipoprotein B, or PCSK9 genes are primary causes.
• FH significantly increases the risk of premature cardiovascular disease, especially in homozygous forms.

Purpose of the Study:

• To review the current understanding of Familial hypercholesterolemia (FH).
• To discuss existing and emerging therapeutic strategies for managing extremely high LDL cholesterol.
• To emphasize the importance of early diagnosis and treatment in reducing cardiovascular events.

Main Methods:

• Literature review of genetic causes, clinical manifestations, and treatment options for FH.
• Analysis of current lipid-lowering therapies including statins, combination therapy, and lipoprotein apheresis.
• Evaluation of novel therapeutic agents targeting lipid metabolism.

Main Results:

• Standard therapies effectively lower LDL cholesterol in heterozygous FH but may be insufficient for severe or homozygous cases.
• Emerging therapies, including PCSK9 inhibitors, MTP inhibitors, and antisense oligonucleotides, show promise for refractory hypercholesterolemia.
• Early intervention is crucial for mitigating the high risk of premature atherosclerosis and cardiovascular events.

Conclusions:

• Familial hypercholesterolemia requires lifelong management due to its profound impact on cardiovascular health.
• A multi-faceted approach combining established and novel therapies is essential for optimizing LDL cholesterol reduction.
• Timely diagnosis and treatment initiation are paramount to prevent premature mortality and morbidity in FH patients.